Good News

http://natap.org/
_______________________________________________
>From Jules: I am at the HCV Drug Resistance Workshop in Bosyon where Mark Sulkowski is delivering the opening talk and discussing IL28b genetic disposition. This gene predicts response to peg/rbv and we know the cc mutation predicts a favorable response to peg/rbv. In fact a recently published japanese study which I distributed found 95% of treatment naive patients who received telaprevir plus peg/rbv achieved SVR. The test will be available commercially soon and will play a very important role in deciding if a patient should begin therapy when the new HCV protease inhibitors are expected to be available in 2011 around September.